PureTech Appoints UBS as UK Corporate Broker




PureTech Appoints UBS as UK Corporate Broker

BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate Broker.

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech’s R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

Contacts

PureTech
Public Relations

publicrelations@puretechhealth.com
Investor Relations

IR@puretechhealth.com

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe




BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

BASEL, Switzerland–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1^st. This appointment will enhance the Company’s commitment to bring impactful medicines to more patients across Europe.

“We are pleased to welcome Giancarlo to BeiGene in what continues to be a transformative journey for us, solidifying our position as a top global oncology innovator. Giancarlo brings a wealth of experience and a proven track record in the pharmaceutical industry, which will be instrumental as we continue to grow our presence in Europe led from our office in Basel, Switzerland. His leadership and vision are a perfect fit for BeiGene, aligning with our commitment to expanding our global footprint and enhancing our capabilities in this vital region. We look forward to the positive impact his expertise will bring to our team and our work,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.

Mr. Benelli is a global executive with over 20 years of experience in the pharmaceutical industry including at Novartis and AstraZeneca. He was most recently Vice President and Head Radioligand Therapy International Markets at Novartis.

“I am honoured and excited to join BeiGene at such a pivotal point in the Company’s growth,” said Mr. Benelli. “BeiGene’s dedication to discovering and developing innovative treatments that are both affordable and accessible resonates deeply with my own personal and professional values. I am eager to connect with more than 800 of our colleagues across Europe to contribute to our shared aspiration of transforming the lives of cancer patients. Together, we will strive to expand our reach and impact in Europe, bringing hope and healing to those who need it most.”

Prior to his role as Head Radioligand Therapy International Markets at Novartis, Mr. Benelli served as General Manager at Advanced Accelerators Applications, where his responsibilities included restructuring the manufacturing, R&D, and commercial organisations in Saint Genis Poully post-Adacap acquisition by Novartis, ensuring business continuity and successfully launching Lutathera in both France and Italy amid post-merger challenges.

Mr. Benelli received a Medical Doctorate degree and a Post Graduate Diploma in Thoracic Surgery, both from University of Genoa, Italy and a Diploma in Health Economics from the University of York, UK.

About BeiGene

BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the expected contributions of Mr. Benelli and their impact on BeiGene, BeiGene’s ability to grow its presence in Europe and expand its global footprint, and BeiGene’s plans, commitments, aspirations and goals under the caption “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

To access BeiGene media resources, please visit our News & Media site.

Contacts

Media Contact:
Maryline Iva

+41 61 685 2090

media@beigene.com

Investor Contact:
Liza Heapes

+1 857-302-5663

ir@beigene.com

JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy




JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy

HYOGO, Japan & TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TOKYO:4552; “JCR”) and Modalis Therapeutics Corporation (TOKYO:4883; “Modalis”) today announced that they have validated the initial proof of concept in a joint research program for the development of a novel gene therapy for a central nervous system (CNS) disease. Due to the success of the partnership thus far, Modalis and JCR have agreed to proceed to the next phase of their research by entering into a new joint research agreement.

The purpose of this joint agreement is to conduct pre-clinical studies for the development of a new gene therapy for the undisclosed CNS disease by applying J-Brain Cargo^®, JCR’s proprietary technology that is able to cross the blood-brain barrier (BBB), and a gene therapy payload based on CRISPR-GNDM^® (Guide Nucleotide-Directed Modulation), Modalis’ proprietary epigenome modulation technology which does not cleave or alter DNA sequences.

The two companies began a joint research collaboration in December of 2023 to evaluate the drug delivery technology of the gene therapy to the CNS. As a result of this research, the initial proof of concept has been validated. The next phase of the agreement is to jointly develop a novel and innovative gene therapy to provide patients with improved efficacy, safety, and less burden via intravenous injection (IV) in a minimally invasive and efficient manner.

“I am pleased to share the progress we’ve achieved in our collaboration with Modalis,” said Hiroyuki Sonoda, Ph.D., Director, Senior Managing Executive Officer, and Executive Director, Research Division at JCR. “By combining our proprietary J-Brain Cargo^® technology for BBB penetration with Modalis’ CRISPR-GNDM^® platform for epigenome editing, we are opening the door to innovative therapeutic possibilities that could make a meaningful difference.”

“We are very happy to move the joint research collaboration with JCR to the next phase,” said Haruhiko Morita, CEO of Modalis. “This is the result of hard work on both companies and an important strategic step for Modalis’ research activities. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse disease model studies, including demonstration of target engagement and safety in non-human primates, exhibiting strong biodistribution for our lead program in neuromuscular disorders. We believe that CRISPR-GNDM^® has huge potential in the field of CNS diseases. So, the combination with J-Brain Cargo^® technology could be a very significant breakthrough to maximize the potential and value of our proprietary epigenome editing technology (CRISPR-GNDM^®) in CNS diseases.”

This announcement is expected to have a minor impact on both companies’ consolidated financial results for this fiscal year (JCR: ending March 2025, Modalis: ending December 2025).

About JCR Pharmaceuticals Co., Ltd.

JCR is a global specialty pharmaceuticals company dedicated to advancing treatments for rare and genetic diseases. With nearly 50 years of expertise in Japan, we are expanding to the US, Europe, and Latin America. Our innovative therapies address conditions like growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. We are also developing treatments for rare diseases like MPS I, MPS II, MPS IIIA and B, and more. Our core values of reliability, confidence, and persistence drive our mission to enhance global medical progress. For more information, visit https://www.jcrpharm.co.jp/en/site/en/.

About Modalis Therapeutics Corporation

Modalis was founded in 2016 and conducts its research and development in Massachusetts, USA. Modalis is a forerunner in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis’ proprietary CRISPR-GNDM^® technology is capable of specifically modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit https://www.modalistx.com/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contacts

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

Modalis Therapeutics Corporation

Corporate Planning Department

media@modalistx.com

$400+ Bn Oncology Pharmaceuticals Markets, 2029 – Increasing Incidence of Cancer Disease and Robust Approval of Oncology Drugs Fuel Growth – ResearchAndMarkets.com




$400+ Bn Oncology Pharmaceuticals Markets, 2029 – Increasing Incidence of Cancer Disease and Robust Approval of Oncology Drugs Fuel Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Oncology Pharmaceuticals Market” report has been added to ResearchAndMarkets.com’s offering.

The global market for oncology pharmaceuticals was valued at $196.4 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 12.7% to reach $401.4 billion by the end of 2029.

This report seeks to deliver an in-depth analysis of the worldwide oncology pharmaceuticals (cancer medications) market. It includes a thorough overview of various types of oncology drugs, such as targeted therapy, immunotherapy, chemotherapy, and hormone therapy, and an examination of current and historical market revenues.

Several factors make the oncology pharmaceutical industry a prime candidate for growth. The oncology pharmaceuticals market is a dynamic and quickly changing sector within the global pharmaceuticals industry. The main priorities of this market are the development, manufacture, and marketing of medications used to treat cancer. It is anticipated to keep expanding due to continuous scientific and technological breakthroughs. Novel immunotherapies and CAR-T cell therapy are emerging treatments that can completely transform how cancer is treated. However, to ensure that new therapies help a wide range of patients, it will be imperative to address issues about drug affordability and accessibility.

The pharmaceutical industry’s pipeline and portfolio in oncology is among the most diverse due to its strong emphasis on research. Over time, improved methods of screening, diagnosis, surgery, and radiation therapy, along with rapidly growing options for systemic treatment, have improved the prognosis for many cancers.

Global funding for cancer research has increased dramatically over the past 20 years, and the rate at which new drugs are being developed has not slowed. The FDA approved 161 new cancer therapeutics between 2017 and 2022 for various solid tumor malignancies and indications. The arsenal of cancer treatments is growing at a very rapid pace, which has led to a significant increase in treatment and regulatory complexity. Cancer treatment is now far more expensive for patients and healthcare systems due to the high cost of many new medications. These difficulties and expenses go beyond solid adult cancers to the pediatric and hematology/oncology fields.

Targeted therapy holds a significant market share regarding medication class, and new precision medicine techniques are emerging from an improved molecular understanding of cancer. As the incidence of breast cancer rises worldwide, pharmaceutical companies are focusing more and more on early diagnosis and treatment options.

Report Scope

The oncology pharmaceuticals market is further categorized by indication, including lung cancer, multiple myeloma, breast cancer, non-Hodgkin’s lymphoma, prostate cancer, colorectal cancer, and other types of cancer. Additionally, the report presents the market revenue for each geographic region, including North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

In order to provide an in-depth understanding of the market, this report also includes profiles of market participants, the competitive landscape, key competitors, and respective market share/ranking. This report includes an oncology pharmaceuticals pipeline analysis, patent analysis, and a detailed discussion of key marketed products. This report outlines the driving and restraining factors of the oncology pharmaceuticals market.

By geography, the market in this report is segmented into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

The report includes:

• 70 data tables and 50 additional tables
• Analysis of the global market for oncology pharmaceuticals (cancer drugs)
• Analyses of global market trends, with market revenue data from 2022 to 2023, estimates for 2024, forecast for 2025, and projected CAGRs through 2029
• An assessment of the different oncology pharmaceutical types (targeted therapy, immunotherapy, chemotherapy and hormone therapy) and their current and historical market revenues
• Estimate of the current market size and revenue prospects, along with a market share analysis by drug type, disease indication (application type), and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
• A Porter’s Five Forces model, and global supply chain and PESTLE analyses
• An analysis of the key products on the market and promising new pipeline molecules or drugs under development
• A look at the recent patent grants
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
• Analysis of the industry structure, including companies’ market shares, strategic alliances, M&A activity and a venture funding outlook
• Company profiles of major players within the industry, including Bristol-Myers Squibb Co., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., and AstraZeneca.

Oncology Pharmaceutical Company Profiles

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Lilly
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.

Key Attributes:

Key Topics Covered:

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Supply Chain Analysis
• Research and Development
• Manufacturing
• Packaging
• Wholesale Distributors and Repackagers
• Pharmacies
• Dispensed to Consumers
• Addressing Challenges in the Pharmaceutical Supply Chain
• Costs
• Regulations
• Safety and Security
• Porter’s Five Forces Analysis in the Oncology Market
• Threat of New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Industry Rivalry

Chapter 3 Market Dynamics

• Market Drivers
• Increasing Incidence of Cancer Disease
• Robust Approval of Oncology Drugs
• Technological Advances in Cancer Treatments
• Market Challenges
• Loss of Exclusivity and Genericization
• Lack of Oncology Professionals

Chapter 4 Emerging Trends and Pipeline Analysis

• Emerging Technologies
• Personalized Cancer Vaccines
• CAR T-Cell Therapy
• Tablet to Cut Breast Cancer Risk
• Nanoparticles
• Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
• New Developments
• Biosimilar Approvals
• Pipeline Analysis
• Clinical Trial Analysis
• Patent Analysis

Chapter 5 Market Segmentation Analysis

• Segmentation Breakdown
• Global Oncology Pharmaceuticals Market by Drug Type
• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Hormone Therapy
• Global Oncology Pharmaceuticals Market by Cancer Type
• Lung Cancer
• Breast Cancer
• Leukemia
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Non-Hodgkin’s Lymphoma
• Colorectal Cancer
• Other Cancers
• Geographic Breakdown
• Global Oncology Pharmaceuticals Market by Region
• North America
• Europe
• Asia-Pacific
• Rest of World

Chapter 6 Competitive Intelligence

• Overview
• Blockbuster Oncology Pharmaceutical Brands
• Global Market Shares of Leading Companies

Chapter 7 Sustainability in the Oncology Pharmaceuticals Market: ESG Perspective

• Role of ESG in the Pharma Industry
• Environmental
• Social
• Governance
• ESG Risk Ratings
• Conclusion

Chapter 8 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/5glqzg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference




Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, M.D., will participate in a company presentation at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. PT (2:15 p.m. ET).

A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website: http://ir.bausch.com/investors/events-presentations.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

© 2025 Bausch + Lomb.

Contacts

Media Contact:
Chris Clark

chris.clark@bausch.com
(848) 360-1100

Investor Contact:
George Gadkowski

george.gadkowski@bausch.com
(877) 354-3705 (toll free)

Exact Sciences to Participate in J.P. Morgan Healthcare Conference




Exact Sciences to Participate in J.P. Morgan Healthcare Conference

MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.

• J.P. Morgan Healthcare Conference, San Francisco
  
  Presentation followed by Q&A on Monday, January 13, 2025 at 1:30 p.m. ET

The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard^® and Oncotype^® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Erik Holznecht

Exact Sciences Corp.

investorrelations@exactsciences.com
608-800-6605

Hamershlag Private Capital Management Limited Makes $150 Million Venture Structured Investment in Patho Care, LLC via PathoCare Holdings, Inc.




Hamershlag Private Capital Management Limited Makes $150 Million Venture Structured Investment in Patho Care, LLC via PathoCare Holdings, Inc.

HOUSTON–(BUSINESS WIRE)–Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced a significant venture investment in Patho Care, LLC, a leader in the “lab on a chip” non-invasive point of care diagnostic tests. Patho Care’s revolutionary Raman spectroscopy-based testing platform is underpinned by 17 patents. The transaction, valued at $150.15 million, was structured as a acquisition and recapitalization using newly issued common stock and cash through a newly formed entity, PathoCare Holdings, Inc., to streamline the investment and operational framework.

This strategic investment reflects HPCM’s commitment to advancing innovative healthcare solutions while generating substantial returns for its investors. The transaction terms were designed to ensure Patho Care, LLC has the resources to expand its operations and establish its market position.

The investment also facilitated the repayment of existing financial obligations held by Patho Care, LLC. As of December 18, 2022, a critical component of the deal included settling PathoCare’s outstanding notes, ensuring the company’s financial readiness to embark on this next phase of growth.

“Patho Care, LLC is a distinguished leader in healthcare diagnostics through the utilization of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries,” said L. Mychal Jefferson, Chairman. “Our commitment to delivering transformative value through innovative investments underscores our confidence in PathoCare’s vision and capabilities.”

The investment will empower Patho Care, LLC to broaden its service offerings, enhance operational efficiencies, and innovate in key areas of diagnostics testing. The collaboration between HPCM and PathoCare Holdings, Inc. is set to unlock new growth opportunities while maintaining the company’s legacy of excellence in an emerging technology.

This venture marks a significant milestone in Hamershlag Private Capital Management Limited’s investment portfolio, reinforcing its reputation as a trusted partner for companies seeking strategic growth capital. Both parties are dedicated to ensuring a seamless transition and maintaining the highest levels of service for PathoCare’s stakeholders.

About Hamershlag Private Capital Management Limited

Hamershlag Private is a family investment office dedicated to investing in category defining companies and projects across industries and sectors. They provide long term, flexible capital with a unique ability to act quickly on impactful opportunities. They maintain a diversified portfolio, with a focus on disruptive technologies, climate impact, and emerging industries by cultivating extensive long-term relationships with other family offices and investment firms across asset classes. Hamershlag Private combines institutional infrastructure with core values of flexibility, creativity, and execution. https://www.hamershlagprivate.com/

About Patho Care, LLC

Patho Care, LLC, a wholly owed subsidiary of PathoCare Holdings, Inc., is a private medical diagnostics firm that has developed a revolutionary Raman Spectroscopy-based testing platform, protected by 17 patents. This innovative technology enables rapid, non invasive, and highly cost effective diagnostic tests, addressing critical limitations in traditional diagnostics. Current testing systems require swabs, reagents, immobile equipment, and several hours to days to obtain test results and are primarily chemical based processes. The PathoCare’s (point-of-care-testing) POCT devices are in the digital domain and therefore programmable, mobile, accurate and reusable for the detection and characterization of any current or future respiratory bacterial or viral infection. The system uses adaptive artificial intelligence to further increase the accuracy of its results via spectral diagnostic and LDT testing confirmation models.

About PathoCare Holdings, Inc.

PathoCare Holdings, Inc. is the newly formed investment and acquisition vehicle created to facilitate Hamershlag Private’s current and future investments and into PathoCare, LLC. www.spectroscopy.health

Contacts

Hamershlag Private Capital Management Limited

718-880-8014

info@hamershlagprivate.com

IPA Announces Resignation of Chief Financial Officer




IPA Announces Resignation of Chief Financial Officer

AUSTIN, Texas–(BUSINESS WIRE)–$IPA #AI—ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time.

“Kristin has been a valued member of our team over this past year,” said Dr. Jennifer Bath, IPA’s President and Chief Executive Officer. “She has made significant contributions to IPA’s success, including the enhancement of IPA’s planning and budgeting process. We wish her the very best in her future endeavors.”

IPA has initiated a CFO succession process and will provide updates as appropriate.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “expects”, “estimates”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or state that certain actions, events, or results “may”, “would”, “might”, or “will” be taken, occur, or be achieved. Forward-looking statements include, but are not limited to, the expected results of our search for a successor to the Chief Financial Officer, the results from our financial strategy and growth objectives. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the United States, Canada or internationally. You should also consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to several factors and risks, as discussed in the Company’s Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (which may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this release. The forward-looking statements contained in this release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

Contacts

Investor Relations Contact
investors@ipatherapeutics.com

Hamershlag Private Capital Markets Limited Makes $150 Million Venture Structured Investment in Patho Care, LLC via PathoCare Holdings, Inc.




Hamershlag Private Capital Markets Limited Makes $150 Million Venture Structured Investment in Patho Care, LLC via PathoCare Holdings, Inc.

HOUSTON–(BUSINESS WIRE)–Hamershlag Private Capital Management Limited (HPCM), a leading health technology investment firm, has announced a significant venture investment in Patho Care, LLC, a leader in the “lab on a chip” non-invasive point of care diagnostic tests. Patho Care’s revolutionary Raman spectroscopy-based testing platform is underpinned by 17 patents. The transaction, valued at $150.15 million, was structured as a acquisition and recapitalization using newly issued common stock and cash through a newly formed entity, PathoCare Holdings, Inc., to streamline the investment and operational framework.

This strategic investment reflects HPCM’s commitment to advancing innovative healthcare solutions while generating substantial returns for its investors. The transaction terms were designed to ensure Patho Care, LLC has the resources to expand its operations and establish its market position.

The investment also facilitated the repayment of existing financial obligations held by Patho Care, LLC. As of December 18, 2022, a critical component of the deal included settling PathoCare’s outstanding notes, ensuring the company’s financial readiness to embark on this next phase of growth.

“Patho Care, LLC is a distinguished leader in healthcare diagnostics through the utilization of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries,” said L. Mychal Jefferson, Chairman. “Our commitment to delivering transformative value through innovative investments underscores our confidence in PathoCare’s vision and capabilities.”

The investment will empower Patho Care, LLC to broaden its service offerings, enhance operational efficiencies, and innovate in key areas of diagnostics testing. The collaboration between HPCM and PathoCare Holdings, Inc. is set to unlock new growth opportunities while maintaining the company’s legacy of excellence in an emerging technology.

This venture marks a significant milestone in Hamershlag Private Capital Markets Limited’s investment portfolio, reinforcing its reputation as a trusted partner for companies seeking strategic growth capital. Both parties are dedicated to ensuring a seamless transition and maintaining the highest levels of service for PathoCare’s stakeholders.

About Hamershlag Private Capital Markets Limited

Hamershlag Private is a family investment office dedicated to investing in category defining companies and projects across industries and sectors. They provide long term, flexible capital with a unique ability to act quickly on impactful opportunities. They maintain a diversified portfolio, with a focus on disruptive technologies, climate impact, and emerging industries by cultivating extensive long-term relationships with other family offices and investment firms across asset classes. Hamershlag Private combines institutional infrastructure with core values of flexibility, creativity, and execution. https://www.hamershlagprivate.com/

About Patho Care, LLC

Patho Care, LLC, a wholly owed subsidiary of PathoCare Holdings, Inc., is a private medical diagnostics firm that has developed a revolutionary Raman Spectroscopy-based testing platform, protected by 17 patents. This innovative technology enables rapid, non invasive, and highly cost effective diagnostic tests, addressing critical limitations in traditional diagnostics. Current testing systems require swabs, reagents, immobile equipment, and several hours to days to obtain test results and are primarily chemical based processes. The PathoCare’s (point-of-care-testing) POCT devices are in the digital domain and therefore programmable, mobile, accurate and reusable for the detection and characterization of any current or future respiratory bacterial or viral infection. The system uses adaptive artificial intelligence to further increase the accuracy of its results via spectral diagnostic and LDT testing confirmation models.

About PathoCare Holdings, Inc.

PathoCare Holdings, Inc. is the newly formed investment and acquisition vehicle created to facilitate Hamershlag Private’s current and future investments and into PathoCare, LLC. www.spectroscopy.health

Contacts

Hamershlag Private Capital Markets Limited

718-880-8014

info@hamershlagprivate.com

A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial




A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial

• Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain following bunionectomy compared to placebo.
• XG005 eliminated the need to use any rescue pain medication in 42% of patients in a high dose group and in 33% of patients in a low dose group.
• For those patients who required rescue analgesics, XG005 increased the time to first use of rescue by 8-fold and it reduced the total amount of opiate consumption medication by 4-fold in a high dose group.
• Patient Global Assessment of pain control was statistically better in XG005 treatment arms than in the placebo group over 72 hours.
• Patients’ sleep post-surgery was significantly improved in the XG005-treated arms as assessed with Sleep Interference Score.
• XG005 was safe and well tolerated with no treatment-related SEs.

SHANGHAI–(BUSINESS WIRE)–#acutepain–Xgene Pharmaceutical announced additional insights into the positive results of a multiple-center, placebo-controlled, dose-ranging Phase 2b study (registration number: NCT06017999) in patients undergoing bunionectomy, evaluating the safety and efficacy of the XG005 oral tablet on acute pain.

XG005 is a non-opioid, new chemical entity with dual mode of action in targeting both nociceptive and neuropathic pain signals. The placebo, 750 mg or 1250 mg of XG005, was administered orally twice a day (bid) for 72 hours to patients undergoing bunionectomy. The study was collaborated with Evolution Research Group and Lotus Clinical Research at multiple sites in the USA. A total of 450 subjects were enrolled into the trial with 1:1:1 randomization ratio. The drug was well tolerated with an acceptable safety profile. There were no drug-related serious adverse events.

The primary and the key secondary efficacy endpoints of SPI over 48 hours for the 1250 mg and 750 mg dose group versus placebo achieved statistically significant difference, respectively with 1250 mg dose providing significantly more analgesia than 750 mg.

Other efficacy endpoints are briefly listed below:

• The pain intensity score was statistically lower in both active arms compared to placebo over 72 hours post-surgery (P< 0.0001); the maximum pain was mild (< 4.0 NRS) in severity in the high dose arm, in contrast to up to severe pain (> 7.0 NRS) score in the placebo arm during the same period (see figure).
• The time to first use of rescue medication was delayed up to 8-fold in the high dose arm compared with placebo, the median times to first use of rescue medication for high dose, low dose and placebo were 31.47, 12.24 and 4.03 hours, respectively, with Hazard Ratios of 0.18 and 0.24 (P< 0.0001).
• Total opioid consumption over 72 hours was significantly less in active arms than in placebo (P< 0.0001), with Morphine Equivalent Dose (MEQ) of 6.72, 9.38 and 23.86/24.68 mg for the high, low dose of XG005 and placebo, respectively.
• Total acetaminophen use (rescue medication) over 72 hours was significantly less in the active arms than in the placebo (P< 0.0001), with means of 1586.03, 1975.89 and 4812.7/4892.74 mg for the high dose, low dose of XG005 and placebo, respectively.
• Patient Global Assessment (PGA) on pain control was statistically greater in XG005 arms than in the placebo arm over 72 hours (P< 0.0001).
• Patients’ sleep post-surgery was significantly better in the XG005-treated arms compared with placebo as assessed with Sleep Interference Score (P< 0.0001).

“I have not seen any analgesics showing such great efficacy in well-controlled multiple center trials. Mean pain severity was mild at the most in high dose group versus severe in placebo group. The amount of rescue medication used, including opioids, was less than 1/3 in the high dose arm compared with placebo. The standard effect sizes for the primary (high dose) and the key secondary (low dose) efficacy endpoints are 1.55 and 1.28, respectively. This compelling efficacy of XG005 overwhelmingly distinguishes it from other analgesics and we are extremely encouraged to expedite the development for early delivery to patients.” said Leon Jiang, Chief Medical Officer at Xgene Pharmaceutical.

“There is a substantial need for more efficacious, safer, non-opioid treatment for acute pain, as many patients are unable to get sufficient relief with currently available medicines due to intolerable side effects. We are pleased that the results from this trial showed the excellent therapeutic effect of XG005, with the potential to be a better treatment option compared to current therapies,” said Gene Hsu, CEO of Xgene. “Xgene is proud to continue its efforts on this unique product, moving forward with great confidence.”

About Acute Pain

Acute pain is defined as pain lasting less than 3 months. In 2023, the acute pain market was valued at approximately USD 50.03 billion and project to reach around USD 78.36 billion by 2032. Due to limited non-opioid treatment options, there is an unmet need in acute pain management to improve the patient experience and reduce the economic and societal burden. (Acute Pain Market Size, Share, Trends & Report | 2032)

About XG005

XG005 is a novel molecule targeting two distinct pain pathways: an anti-nociceptive and an anti-neuropathic. It is potentially first-in-class oral treatment that is in parallel development for treatment of acute and chronic pain conditions. Due to its dual mechanism of action, XG005 is potentially able to provide greater inhibition of the pain signal transmission achieving better analgesic outcomes while providing good safety profile.

A positive phase 2b trial results of XG005 treatment in chronic osteoarthritis pain was recently reported, and a Phase 2 trial of XG005 in cancer-induced bone pain is currently ongoing in Taiwan and Mainland of China.

About Xgene Pharmaceutical: Transforming Medicine for Better Lives

At Xgene, we apply new clinical findings, science, and innovative technology to bring therapies to patients to extend and significantly improve their lives. We strive for quality, safety and value in our new products. Our goal is to deliver the world’s best medicine to patients worldwide. Xgene’s drug discovery areas include pain and CNS conditions focusing research on finding treatments and cures for unmet medical needs. We collaborate with health care providers, governments, and local communities to identify patient needs and deliver reliable, affordable medicines around the world. Visit our website at www.xgenepharm.com.

Contacts

Direct further inquiries to Dr. Iwona Beczkowska iwona.beczkowska@xgenepharm.com